Status:
COMPLETED
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
Lead Sponsor:
Bayer
Conditions:
Hemophilia A
Eligibility:
MALE
Brief Summary
The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGEN...
Eligibility Criteria
Inclusion
- Patients with diagnosis of haemophilia A, treated with KOGENATE Bayer/FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE Bayer/FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.
Exclusion
- Exclusion criteria must be read in conjunction with the local product information.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
405 Patients enrolled
Trial Details
Trial ID
NCT00874926
Start Date
June 1 2008
End Date
April 1 2013
Last Update
January 29 2014
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Bahrain
2
Many Locations, Bosnia and Herzegovina
3
Many Locations, Croatia
4
Many Locations, Germany